- Home
- UFCS vs PHAR Comparison
UFCS vs PHAR Comparison
Compare UFCS & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- PHAR
- Stock Information
- Founded
- UFCS 1946
- PHAR 1988
- Country
- UFCS United States
- PHAR Netherlands
- Employees
- UFCS N/A
- PHAR N/A
- Industry
- UFCS Property-Casualty Insurers
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- PHAR Health Care
- Exchange
- UFCS Nasdaq
- PHAR Nasdaq
- Market Cap
- UFCS 642.7M
- PHAR 679.0M
- IPO Year
- UFCS N/A
- PHAR N/A
- Fundamental
- Price
- UFCS $25.27
- PHAR $9.10
- Analyst Decision
- UFCS Hold
- PHAR Strong Buy
- Analyst Count
- UFCS 1
- PHAR 3
- Target Price
- UFCS $26.00
- PHAR $27.00
- AVG Volume (30 Days)
- UFCS 133.8K
- PHAR 6.7K
- Earning Date
- UFCS 02-11-2025
- PHAR 03-13-2025
- Dividend Yield
- UFCS 2.52%
- PHAR N/A
- EPS Growth
- UFCS N/A
- PHAR N/A
- EPS
- UFCS 1.94
- PHAR N/A
- Revenue
- UFCS $1,207,451,000.00
- PHAR $285,745,000.00
- Revenue This Year
- UFCS N/A
- PHAR $20.08
- Revenue Next Year
- UFCS $11.31
- PHAR $9.22
- P/E Ratio
- UFCS $12.99
- PHAR N/A
- Revenue Growth
- UFCS 10.95
- PHAR 30.64
- 52 Week Low
- UFCS $18.04
- PHAR $6.65
- 52 Week High
- UFCS $31.70
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- UFCS 32.68
- PHAR 46.44
- Support Level
- UFCS $25.20
- PHAR $9.37
- Resistance Level
- UFCS $27.06
- PHAR $10.01
- Average True Range (ATR)
- UFCS 0.87
- PHAR 0.55
- MACD
- UFCS -0.18
- PHAR -0.14
- Stochastic Oscillator
- UFCS 1.93
- PHAR 16.26
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.